Imagine a tiny, high-tech filter that can spot a single needle in a haystack of blood. Instead of using slow chemical reactions to amplify signals, it uses magnetic particles to shuttle light-emitting tracers to a sensor. This allows doctors to see both genetic markers and proteins at once, providing a much clearer picture of a disease.
Current liquid biopsy methods often require separate, slow, and enzyme-dependent tests for DNA and proteins. This creates a gap in fast, integrated diagnostic tools for complex diseases like cancer.
A proof-of-concept diagnostic system featuring a second-generation microfluidic chip, an integrated hardware prototype, and specialized nanobody-based sensor chips.
If you are a cancer screening lab dealing with the need for more precise liquid biopsies — this project developed a proteogenomic test that analyzes DNA and proteins together. This allows for better cancer management using biobanked samples.
If you are an IVD manufacturer dealing with the limitations of enzyme-based digital PCR or ELISA — this project developed an enzyme-free amplification strategy. It uses microfluidic chips and magnetic transport to detect single molecules.
If you are a drug discovery firm dealing with the need to monitor multiple biomarkers for neuro-degenerative or cardiovascular diseases — this project developed a versatile amplification method. It enables fast, easy-to-use tests for various significant diseases.
Based on available project data, the cost and pricing details are not specified as the project is focused on proof-of-concept development.
The project is currently developing a proof-of-concept and hardware prototypes. Based on available project data, industrial scaling plans are not yet detailed.
Based on available project data, specific patent or licensing terms are not listed, though the project involves the development of a novel affinity-mediated-transport amplification method.
The project period is from 2022-04-01 to 2026-03-31, spanning 4 years.
The system integrates microfluidic chips with an integrated hardware prototype to process liquid biopsy samples in a clinical setting.
The consortium is well-balanced for technology transfer, consisting of 8 partners across 4 countries. With an industry ratio of 38% (including 3 SMEs), there is a strong bridge between the 2 universities and 2 research centers and the commercial market, ensuring the hardware prototype is designed with industrial applicability in mind.
Contact TEKNOLOGIAN TUTKIMUSKESKUS VTT OY in Finland
Contact us to explore licensing opportunities for this proteogenomic platform.
